Checkpoint inhibitor (CPI) therapy revolutionized treatment for advanced non-small cell lung cancer (NSCLC); however, most patients progress due to primary or acquired resistance. Sitravatinib is a receptor tyrosine kinase inhibitor that can shift the immunosuppressive tumor microenvironment towards an immunostimulatory state. Combining sitravatinib with nivolumab (sitra+nivo) may potentially overcome initial CPI resistance.
Tag: Lung Cancer
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
Acral melanoma (AM) has distinct characteristics as compared with cutaneous melanoma and exhibits poor response to immune checkpoint inhibitors (ICIs). Tumor-intrinsic mechanisms of immune exclusion have been identified in many cancers but less studied in AM. We characterized clinically annotated tumors from patients diagnosed with AM at our institution in correlation with ICI response using… Continue reading Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase
Several generations of ATP-competitive anti-cancer drugs that inhibit the activity of the intracellular kinase domain of the epidermal growth factor receptor (EGFR) have been developed over the past twenty years. The first-generation of drugs such as gefitinib bind reversibly and were followed by a second-generation such as dacomitinib that harbor an acrylamide moiety that forms… Continue reading A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
Background Systemic immune activation, hallmarked by C-reactive protein (CRP) and interleukin-6 (IL-6), can modulate antitumor immune responses. In this study, we evaluated the role of IL-6 and CRP in the stratification of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We also interrogated the underlying immunosuppressive mechanisms driven by the… Continue reading Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
25 Years of Trastuzumab: A Legacy of Innovation
AI SummaryThe AACR Annual Meeting 2023 celebrated the 25th anniversary of the breast cancer drug trastuzumab (Herceptin). Trastuzumab’s development revolutionized drug discovery and inspired other HER2-targeted therapies. These include small molecule inhibitors, antibody-drug conjugates, and bispecific antibodies. Researchers are also exploring new approaches, such as CAR T-cell therapy, to overcome resistance to existing HER2-targeted treatments.… Continue reading 25 Years of Trastuzumab: A Legacy of Innovation
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
The IMpower010 and KEYNOTE-091 trials have demonstrated the benefit of adjuvant immunotherapy (IO) after chemotherapy (C+IO) in resected non-small cell lung cancer (NSCLC), including those with epidermal growth factor receptor gene (EGFR) mutation. Meanwhile, several studies have reported that EGFR-tyrosine kinase inhibitor (EGFR-TKI) may prolong disease-free survival (DFS) in these patients. However, there is currently… Continue reading Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
Abstract Background Based on a high incidence of genomic alteration in the cell cycle and DNA damage and response (DDR)-related pathways in small cell lung cancer (SCLC), the clinical efficacy of the DDR-targeting agent olaparib (PARP inhibitor) as monotherapy and in combination with ceralasertib (ATR inhibitor) in relapsed or refractory SCLC was evaluated. Methods As… Continue reading Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
AI SummaryThe efficacy of olaparib (PARP inhibitor) as monotherapy or in combination with ceralasertib (ATR inhibitor) in treating relapsed or refractory small cell lung cancer (SCLC) was evaluated. The combination showed better disease stabilization than monotherapy, but neither treatment met the efficacy target. More research is needed to explore different combinations and patient selection strategies… Continue reading Biomarker‐driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer
AI SummarySexual dysfunction is prevalent in women with lung cancer, with most reporting little to no interest in sexual activity and minimal satisfaction with their sex life. Factors such as fatigue and feeling sad/unhappy contribute to low satisfaction. Lack of interest and vaginal dryness or pain are common reasons for lack of recent sexual activity.… Continue reading Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer
Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer
Abstract Background Sexual health is understudied and underreported in patients with lung cancer, and most data precede the approval of widely used targeted therapies and immune checkpoint inhibitors. The authors sought to evaluate the prevalence of sexual dysfunction in women with lung cancer in our current clinical environment. Methods This cross-sectional survey study was administered… Continue reading Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer